Boehringer Ingelheim (BI) and Eli Lilly (NYSE: LLY) have announced the receipt of marketing approval from the National Medical Products Administration (NMPA) for their SGLT2 inhibitor Jardiance (empagliflozin) aimed at treating adult chronic kidney disease (CKD). This pivotal approval marks a significant advancement in the management of CKD, further establishing Jardiance as a key player in chronic disease treatment.
Clinical Evidence from the EMPA-KIDNEY Study
The NMPA approval is supported by robust data from the EMPA-KIDNEY study, which revealed that Jardiance significantly reduced the relative risk of kidney disease progression or cardiovascular death events by 28% compared to placebo. Additionally, the study demonstrated a 14% reduction in the relative risk of hospitalization for any reason. Importantly, the safety profile of Jardiance remains consistent with prior reports, reinforcing its therapeutic potential.
Expanding Therapeutic Applications
Previously, Jardiance received NMPA approval for the treatment of heart failure and type 2 diabetes (T2D), showcasing its versatility across multiple health conditions. With this latest indication for chronic kidney disease, Boehringer Ingelheim and Eli Lilly are well-positioned to enhance patient outcomes and solidify Jardiance’s role in comprehensive chronic disease management.- Flcube.com
